iTAF13-26, iTAF13del26
ICGi013-A
General
Cell Line |
|
hPSCreg name | ICGi013-A |
Cite as: | ICGi013-A (RRID:CVCL_WU29) |
Alternative name(s) |
iTAF13-26, iTAF13del26
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
|
Last update | 29th November 2019 |
User feedback | |
Provider |
|
Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
Owner | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
Distributors | |
Derivation country | Russia |
External Databases |
|
BioSamples | SAMEA5859254 |
Cellosaurus | CVCL_WU29 |
Wikidata | Q94313435 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
arr[hg18]3p26.3(1,172,623-1,467,721) × 1, 10q11.22(45,478,103-47,125,152) × 3
Karyotyping method:
Array CGH
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA5859255 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | No |
Is there other documentation provided to the donor for consenting purposes? | No |
Has the donor agreed to be re-contacted? | Unknown |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | No |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | Yes |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | No |
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | No |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | No |
a public organisation? | No |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | No |
Does consent expressly permit storage of genetic information? | No |
Does consent prevent dissemination of genetic information? | No |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | No |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMC |
Approval number | protocol number 106/2017 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMC |
Approval number | protocol number 106/2017 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
Is there an MTA available for the cell line? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | DNA vectors were kindly gifted by Kiselev S.L. |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
Source cell line name |
TAF13del Derived from same source line (potentially other lot and donor, see below):
|
Source cell type |
Synonyms
|
Source cell origin |
The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb.
Synonyms
|
Passage number reprogrammed | 8 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Lentivirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
No |
Reprogramming vectors silenced? |
Unknown |
Vector map | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzymatically
Accutase
|
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|||||
TRA 1-60 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
SSEA-4 |
Yes |
|
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
AFP |
Yes |
SOX17 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
TBXT |
Yes |
FLK1 |
Yes |
MSX1 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
MAP2 |
Yes |
SOX1 |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.